Editorials

Regulation of opioid prescribing

BMJ 2007; 334 doi: https://doi.org/10.1136/bmj.39175.458275.BE (Published 19 April 2007) Cite this as: BMJ 2007;334:811
  1. Jane C Ballantyne, chief, division of pain medicine
  1. Pain Center, Massachusetts General Hospital, MA 02114, USA
  1. jballantyne{at}partners.org

    Over-regulation compromises doctors' ability to treat pain

    Long before the discovery of endogenous opioid systems, opium was used to produce insensibility and relieve pain. Societies began regulating opiates when the availability and use of opiate drugs reached a level that made opiate addiction a problem to society. In the United Kingdom and the United States this was at the beginning of the 20th century, with the Drug Enforcement Act in the UK (1920) and the Harrison Act in the US (1918). Before regulations, opiates were widely available in chemist shops, doctors' surgeries, and opium dens, and the choice of use was entirely up to the individual, with the risk of addiction being understood. None the less, a stigma was attached to the use of opiates, even therapeutically, but nothing like that seen after regulations made the use of opiates, other than by prescription, a criminal offence. Once these regulations were introduced, a hugely profitable illicit trade in opiates began. This, along with the increasing problems in society attributed to abuse of opiates and other drugs, inevitably compounded the stigma attached to these drugs and affected the use of opiates for relieving pain.

    Pain advocacy—lobbying for (opiate) treatment of pain—is a powerful movement in the US, more so than in the UK. …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe